Table 2.

Comparison of least square mean placebo-adjusted change from baseline in 12-lead Holter QTcI (ms) between TAS-102 and placebo

Day	Postdose hour	TAS-102		Placebo		TAS-102 versus placebo
		N	LS meansa	N	LS meansa	Difference	90 % CI
1	0	27	−1.9	27	−0.3	−1.6	(−5.6, 2.4)
	0.25	27	−0.9	28	−1.6	0.7	(−3.3, 4.7)
	0.5	29	−1.3	28	−4.0	2.7	(−1.2, 6.6)
	1	29	−2.0	29	−2.2	0.2	(−3.7, 4.1)
	2	28	−0.9	30	−0.6	−0.3	(−4.2, 3.6)
	4	30	2.2	27	−1.9	4.1	(0.2, 8.1)
	6	28	−3.4	29	−2.6	−0.8	(−4.8, 3.1)
	8	28	−1.5	25	−3.3	1.8	(−2.3, 5.9)
	10	28	−1.3	28	−3.5	2.2	(−1.7, 6.2)
	12	21	−0.1	15	−4.9	4.8	(−0.3, 9.8)
12	0	26	−0.9	27	−0.4	−0.5	(−5.6, 4.5)
	0.25	28	−1.3	28	−1.6	0.3	(−4.6, 5.2)
	0.5	29	−1.8	28	−3.6	1.8	(−3.1, 6.7)
	1	29	−3.3	29	−2.1	−1.1	(−6.0, 3.7)
	2	28	−2.1	30	−0.6	−1.5	(−6.3, 4.4)
	4	29	−0.4	27	−1.4	1.0	(−3.9, 5.9)
	6	30	−3.4	29	−2.5	−1.0	(−5.7, 3.8)
	8	27	0.3	25	−3.3	3.6	(−1.5, 8.7)
	10	26	−3.9	28	−3.3	−0.7	(−5.7, 4.3)
	12	19	0.2	15	−3.7	3.9	(−2.5, 10.3)

LS least square; CI confidence interval

^aRepeated measures analysis of variance (ANOVA) model: change from baseline in QTcI result = Treatment + Time + Treatment × Time. Compound symmetry covariance was used. Measurements at different time points within each patient’s treatment were treated as repeated measures